CVL-936 is under clinical development by Cerevel Therapeutics and currently in Phase I for Substance (Drug) Abuse. According to GlobalData, Phase I drugs for Substance (Drug) Abuse have a 72% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how CVL-936’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CVL-936 is under development for the treatment of substance use disorder. The drug candidate is administered through oral route in the form of suspension and solution. It acts by targeting D3.
Cerevel Therapeutics overview
Cerevel Therapeutics is a biopharmaceutical company. It develops and commercializes medicines for the treatment of central nervous system (CNS) disorders. Cerevel Therapeutics is headquartered in Boston, Massachusetts, United States.
For a complete picture of CVL-936’s drug-specific PTSR and LoA scores, buy the report here.